Alessandro D Santin Selected Research

sacituzumab govitecan

1/2021	Novel antibody-drug conjugates: current and future roles in gynecologic oncology.
9/2020	Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer.
2/2020	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.
1/2020	Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
1/2020	In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
1/2020	Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.
1/2019	Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
8/2018	Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandro D Santin Research Topics

Disease

130	Neoplasms (Cancer) 03/2022 - 02/2002
70	Carcinoma (Carcinomatosis) 01/2022 - 11/2003
42	Ovarian Neoplasms (Ovarian Cancer) 02/2022 - 02/2002
38	Endometrial Neoplasms (Endometrial Cancer) 03/2022 - 08/2004
28	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2021 - 12/2002
16	Papillary Carcinoma 01/2019 - 10/2004
15	Ovarian Epithelial Carcinoma 12/2021 - 02/2007
13	Carcinosarcoma 01/2022 - 06/2007
8	Neoplasm Metastasis (Metastasis) 02/2022 - 11/2003
7	Disease Progression 10/2021 - 08/2008
6	Ascites 02/2022 - 06/2004
6	Adenocarcinoma 01/2020 - 09/2008
5	Ovarian Diseases (Ovarian Disease) 12/2015 - 07/2009
5	Endometrioid Carcinoma 12/2011 - 05/2005
3	Breast Neoplasms (Breast Cancer) 02/2022 - 06/2003
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2019 - 06/2011
3	Uterine Neoplasms (Uterine Cancer) 01/2018 - 06/2004
3	Infections 01/2012 - 07/2009
2	COVID-19 01/2022 - 06/2021
2	Nausea 11/2020 - 01/2020
2	Pain (Aches) 11/2020 - 09/2011

Drug/Important Bio-Agent (IBA)

32	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2005
18	Trastuzumab (Herceptin)FDA Link 11/2021 - 05/2002
14	Paclitaxel (Taxol)FDA LinkGeneric 02/2022 - 08/2004
14	PlatinumIBA 01/2022 - 08/2007
14	Immunoconjugates (Immunoconjugate)IBA 11/2021 - 10/2014
12	ParaffinIBA 01/2020 - 11/2003
12	Claudin-3IBA 01/2019 - 10/2004
11	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2005
11	Monoclonal AntibodiesIBA 10/2018 - 02/2004
10	AntigensIBA 01/2021 - 02/2002
9	Clostridium enterotoxinIBA 01/2017 - 05/2005
9	Messenger RNA (mRNA)IBA 07/2013 - 06/2007
8	sacituzumab govitecanIBA 01/2021 - 08/2018
8	Claudin-4IBA 01/2019 - 10/2004
8	Epithelial Cell Adhesion MoleculeIBA 01/2016 - 10/2004
7	Immune Checkpoint InhibitorsIBA 03/2022 - 01/2016
7	Carboplatin (JM8)FDA LinkGeneric 02/2022 - 08/2004
7	Peptides (Polypeptides)IBA 12/2015 - 05/2005
7	EnzymesIBA 07/2009 - 01/2004
6	TubulinIBA 02/2022 - 04/2012
6	neratinibIBA 01/2022 - 10/2014
6	EpitopesIBA 11/2021 - 05/2005
6	Formaldehyde (Formol)FDA Link 01/2020 - 10/2004
6	Epidermal Growth Factor (EGF)IBA 11/2016 - 08/2004
6	Interleukin-2 (IL2)IBA 12/2011 - 08/2003
6	Serine Proteases (Serine Protease)IBA 02/2009 - 11/2003
5	taxaneIBA 01/2022 - 07/2013
5	pembrolizumabIBA 01/2022 - 01/2018
5	VaccinesIBA 01/2021 - 01/2005
5	Tyrosine Kinase InhibitorsIBA 10/2020 - 04/2013
5	Pharmaceutical PreparationsIBA 01/2020 - 10/2010
5	CytokinesIBA 01/2016 - 06/2003
5	epothilone B (EPO906)IBA 01/2014 - 10/2010
5	Oncogene Proteins (Oncogene Protein)IBA 07/2009 - 05/2003
4	ixabepilone (BMS 247550)FDA Link 01/2022 - 07/2013
4	trastuzumab duocarmazineIBA 01/2021 - 01/2016
4	Ado-Trastuzumab EmtansineIBA 01/2021 - 01/2017
4	Biological ProductsIBA 01/2020 - 11/2003
4	OligonucleotidesIBA 03/2007 - 10/2004
4	Kallikreins (Kallikrein)IBA 05/2006 - 08/2004
4	Peptide Hydrolases (Proteases)FDA Link 10/2004 - 11/2003
3	Bevacizumab (Avastin)FDA Link 01/2022 - 06/2015
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 08/2004
3	olaparibIBA 01/2022 - 10/2019
3	copanlisibIBA 08/2020 - 11/2019
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 01/2019
3	Surface Antigens (Surface Antigen)IBA 01/2020 - 01/2020
3	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2020 - 12/2010
3	DNA (Deoxyribonucleic Acid)IBA 11/2019 - 02/2013
3	Aromatase InhibitorsIBA 01/2019 - 08/2007
3	DuocarmycinsIBA 10/2017 - 01/2016
3	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 01/2017 - 04/2015
3	IntegrinsIBA 11/2016 - 03/2007
3	SolitomabIBA 01/2016 - 02/2015
3	ChromiumIBA 01/2016 - 06/2006
3	Epothilones (Epothilone)IBA 07/2013 - 01/2013
3	Mammaglobin BIBA 07/2013 - 06/2007
3	Complement System Proteins (Complement)IBA 05/2012 - 09/2007
3	adecatumumabIBA 12/2010 - 01/2010
3	RNA (Ribonucleic Acid)IBA 07/2009 - 11/2006
3	ImmunosorbentsIBA 07/2009 - 07/2005
3	1-oleoyl-2-stearoylphosphatidylcholineIBA 03/2007 - 10/2004
2	LipidsIBA 02/2022 - 06/2004
2	Oxygen (Dioxygen)IBA 01/2022 - 06/2021
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2022 - 10/2019
2	Adenosine Diphosphate Ribose (ADP-Ribose)IBA 01/2022 - 10/2019
2	Adenosine Diphosphate (ADP)IBA 01/2022 - 10/2019
2	Taxoids (Taxanes)IBA 12/2021 - 05/2014
2	pertuzumabIBA 11/2021 - 10/2017
2	Folic Acid (Vitamin M)FDA LinkGeneric 01/2021 - 01/2018
2	mirvetuximab soravtansineIBA 01/2021 - 01/2018
2	MesothelinIBA 01/2021 - 01/2020
2	Angiogenesis InhibitorsIBA 01/2021 - 01/2016

Therapy/Procedure

63	Drug Therapy (Chemotherapy) 01/2022 - 05/2002
60	Therapeutics 01/2022 - 05/2002
28	Immunotherapy 01/2021 - 02/2002
8	Radiotherapy 01/2021 - 12/2002
4	Salvage Therapy 01/2018 - 06/2003
3	Precision Medicine 01/2017 - 05/2013